Phase III Cat-PAD Follow-on Study

An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment

The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment. The study is an optional follow-up study to a phase III double-blind, placebo controlled, Cat-PAD study; no further investigational product is administered.

Inclusion Criteria:

• previously completed clinical study CP007 [NCT01620762]

Exclusion Criteria:

• started allergen therapy since completing CP007
• Institutionalised due to a legal or regulatory order